C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Last day of dealings and update on Cancellation

25 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a further update with regards to the proposed cancellation of admission of the Company's ordinary shares to trading on AIM (the "Cancellation"), as originally announced on 27 March 2024 and as approved by shareholders at the general meeting held on 15 April 2024.

Shareholders are reminded that the last day of trading in the Ordinary Shares on AIM is today, 25 April 2024, and Cancellation will become effective at 7:00 a.m. on 26 April 2024. Following Cancellation, the Company will re-register as a private company under the name C4X Discovery Holdings Limited.

As previously announced, the Company has engaged Asset Match (www.assetmatch.com), a firm Authorised and Regulated by the Financial Conduct Authority (FRN 579310), to operate an electronic off-market dealing facility for the ordinary shares. This facility will allow existing shareholders of the Company and new investors to trade ordinary shares by matching buyers and sellers through periodic auctions. Further details can be found on the Company's website www.c4xdiscovery.com. The Asset Match facility will be effective from 8 a.m. on 26 April 2024.  Investors may wish to register on www.assetmatch.com and add C4X Discovery to their 'Watchlist' to continue to receive auction/price information and updates.

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. Shareholders wishing to trade shares through Asset Match must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the Asset Match platform is available on request.

Following Cancellation, shareholders are encouraged to sign up to the Company's email news alerts via the C4XD website to remain up to date with the Company's developments as we continue to advance our portfolio and target opportunities as a private company.

Further details regarding the cancellation and re-registration are set out in the circular sent to shareholders dated 27 March 2024. A copy of the circular is available on the Company's website www.c4xdiscovery.com.

Following Cancellation, Panmure Gordon (UK) Limited will cease to act as nominated adviser and corporate broker to the Company.

- Ends -

Contacts

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

About Asset Match

Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on-screen together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" single clearing price ("Share Price") based on supply and demand and allocates transactions accordingly. Bids and offers may be made, amended and withdrawn at any time before the closing date of each auction.

For more information, see www.assetmatch.com